EP1490324A4 - Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors - Google Patents

Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors

Info

Publication number
EP1490324A4
EP1490324A4 EP03716197A EP03716197A EP1490324A4 EP 1490324 A4 EP1490324 A4 EP 1490324A4 EP 03716197 A EP03716197 A EP 03716197A EP 03716197 A EP03716197 A EP 03716197A EP 1490324 A4 EP1490324 A4 EP 1490324A4
Authority
EP
European Patent Office
Prior art keywords
propargylamino
derivatives
brain
tetralin
indan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03716197A
Other languages
German (de)
French (fr)
Other versions
EP1490324A2 (en
Inventor
Eran Blaugrund
Yaacov Herzig
Jeffrey Sterling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1490324A2 publication Critical patent/EP1490324A2/en
Publication of EP1490324A4 publication Critical patent/EP1490324A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
EP03716197A 2002-02-27 2003-02-27 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors Withdrawn EP1490324A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8567402A 2002-02-27 2002-02-27
US85674 2002-02-27
PCT/US2003/005871 WO2003072055A2 (en) 2002-02-27 2003-02-27 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors

Publications (2)

Publication Number Publication Date
EP1490324A2 EP1490324A2 (en) 2004-12-29
EP1490324A4 true EP1490324A4 (en) 2007-10-10

Family

ID=27765338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03716197A Withdrawn EP1490324A4 (en) 2002-02-27 2003-02-27 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors

Country Status (5)

Country Link
EP (1) EP1490324A4 (en)
JP (1) JP2005523289A (en)
AU (1) AU2003219913A1 (en)
CA (1) CA2477218A1 (en)
WO (1) WO2003072055A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
NZ560660A (en) 2005-02-23 2010-11-26 Teva Pharma Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity
US8022104B2 (en) 2005-02-24 2011-09-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations of ladostigil tartrate
WO2006130707A2 (en) * 2005-06-02 2006-12-07 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CN101262867A (en) 2005-07-01 2008-09-10 叶林发现公司 MAO-B inhibitors useful for treating obesity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011761A1 (en) * 1991-12-18 1993-06-24 H. Lundbeck A/S Aryl-triflates and related compounds
WO1996036596A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
EP0697894A4 (en) * 1993-03-31 1996-05-01 Univ Pennsylvania Dopamine d-3 and serotonin (5-ht 1a?) receptor ligands and imaging agents
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
AU710825B2 (en) * 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
DK0966435T3 (en) * 1996-12-18 2005-08-15 Teva Pharma Aminoindane derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011761A1 (en) * 1991-12-18 1993-06-24 H. Lundbeck A/S Aryl-triflates and related compounds
WO1996036596A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHUMPRADIT, SUMALEE ET AL: "Synthesis and optical resolution of (R)- and (S)-trans-7-hydroxy-2- [N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand", XP002434898, retrieved from STN Database accession no. 1994:8313 *
HAZELHOFF, BERNARD ET AL: "N-Methyl,N-propargyl-2-aminotetralins: novel dopamine agonists with monoamine oxidase inhibiting properties", EUROPEAN JOURNAL OF PHARMACOLOGY , 109(2), 229-40 CODEN: EJPHAZ; ISSN: 0014-2999, 1985, XP002434896 *
JOURNAL OF MEDICINAL CHEMISTRY , 36(26), 4308-12 CODEN: JMCMAR; ISSN: 0022-2623, 1993 *
R. SARGES, J.R. TRETTER, S.S. TENEN, A. WEISSMAN: "5,8-Disubstituted 1-Aminotetralines. A Class of Compounds with a Novel Profile of Central Nervous System Activity.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, 1973, pages 1003 - 1011 *
STERLING, JEFFREY ET AL: "Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease", JOURNAL OF MEDICINAL CHEMISTRY , 45(24), 5260-5279 CODEN: JMCMAR; ISSN: 0022-2623, 2002, XP002296523 *
Y.C. MARTIN, C.H. JARBOE, R.A. KRAUSE, K.R. LYNN, D. DUNNIGAN, J.B. HOLLAND: "Potential Anti-Parkinson Drugs Designed by Receptor Mapping", JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, 1973, pages 147 - 150 *

Also Published As

Publication number Publication date
AU2003219913A1 (en) 2003-09-09
AU2003219913A8 (en) 2003-09-09
EP1490324A2 (en) 2004-12-29
WO2003072055A3 (en) 2003-12-31
WO2003072055A2 (en) 2003-09-04
JP2005523289A (en) 2005-08-04
CA2477218A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
IS7749A (en) Pyrimidine derivatives and their use as CB2 direct
AUPS138502A0 (en) Browsing tools and methods
EP1539941A4 (en) Adzymes and uses thereof
AU2003259271A1 (en) Bipolar articles and related methods
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
PL372123A1 (en) Thiazole derivatives
SI1499589T1 (en) Derivatives of n-phenyl(piperidin-2-yl)methyl benzamide, the preparation method thereof and application of same in therapeutics
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
EG25683A (en) Benzoxazine derivatives and uses thereof
AU2003243594A8 (en) Novel boronic chalcone derivatives and uses thereof
AU2003216221A1 (en) Attachment and articles using same
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
SI1551805T1 (en) Substituted gamma-phenyl-delta-lactams and uses related thereto
AU2003285914A8 (en) Dynamic management of execute in place applications
AU2003219913A8 (en) Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
PL375416A1 (en) Thiazole derivatives
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
EP1553101A4 (en) N-acetylglucosamine derivatives and use thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
DE60323960D1 (en) ENZEN 900 AND 1800 MHZ
DE50306262D1 (en) Peeling and burnishing tool
GB0220776D0 (en) FOXP2 and uses thereof
DE60311722D1 (en) Bolts and dies
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040923

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20070907

17Q First examination report despatched

Effective date: 20081112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100619